SAN DIEGO, March 24, 2015 /PRNewswire/ -- Sequenom
Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ:
SQNM), a life sciences company committed to enabling healthier
lives through the development of innovative products and services,
announced today that it will be presenting six scientific posters
on noninvasive prenatal testing (NIPT) and supporting a continuing
medical education (CME) satellite symposium through an unrestricted
educational grant at the American College of Medical Genetics and
Genomics (ACMG) Annual Clinical Genetics Meeting, which will be
held March 24-28, 2015 in
Salt Lake City, Utah.
Sequenom Laboratories Scientific Posters at
ACMG
Thursday, March 26,
10:30 a.m. – 12 p.m. and Friday, March
27, 10:30 a.m. – 12 p.m.
Salt Palace Convention Center, Exhibit Hall ABC
- Poster #354: Updated clinical experience of trisomy 16 and 22,
and microdeletion detection by noninvasive prenatal testing
(NIPT).
- Poster #428: Automated genomic interpretation of
sub-chromosomal fetal copy number variation by sequencing
circulating cell-free DNA from maternal plasma.
- Poster #681: Circulating cell-free DNA screening for fetal
aneuploidy: the Newton-Wellesley Hospital Maternal Fetal Medicine
experience.
- Poster #683: Rings and things: Noninvasive prenatal
testing's unique view of the biology and embryology behind
chromosomal ring formation and segregation.
- Poster #694: Two cases of Wolf-Hirschhorn syndrome detected by
noninvasive prenatal testing (NIPT).
- Poster #708: Noninvasive prenatal testing aids in detecting
parental balanced translocation and highlights limitations of
karyotyping.
The posters showcase recent research and clinical applications
associated with the MaterniT21® PLUS NIPT
technology.
"The Next-Gen Informed Consent for Prenatal Testing" CME
Symposium
Friday, March 27, 7:15 a.m.-8:45 a.m. at the Salt Palace Convention
Center
This continuing medical education event will explore the principles
of informed consent and the challenges of its application in the
busy prenatal practice. It will include an overview of key issues
in NIPT consenting and models that may meet the needs of patients,
providers, and laboratories. The symposium is accessible by
registered ACMG attendees only.
In recent company news, Sequenom Laboratories in partnership
with Recombine Inc., a clinical genetic testing company dedicated
to helping patients and providers make informed healthcare
decisions, announced the launch of the HerediT®
UNIVERSAL carrier screening test as a service to ordering
physicians. The HerediT UNIVERSAL test screens for more than 250
genetic disorders by analyzing over 2,000 genetic mutations.
Current options are limited to single gene testing or tests that
can identify approximately 100 hereditary conditions. The HerediT
UNIVERSAL test can be performed preconception or at any time during
pregnancy.
More information about the HerediT UNIVERSAL and MaterniT21 PLUS
tests will be available at Sequenom Laboratories' booth #805.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier
lives through the development of innovative products and
services. The Company serves patients and physicians by
providing early patient management information. To learn
more, visit www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified
molecular diagnostics laboratory, has developed a broad range of
laboratory tests, with a focus principally on prenatal care.
Branded under the names HerediT®, MaterniT21®
PLUS, SensiGene® and VisibiliT™, these
molecular genetic laboratory-developed tests provide early patient
management information for obstetricians, geneticists, and maternal
fetal medicine specialists. Sequenom Laboratories is changing the
landscape in genetic diagnostics using proprietary cutting edge
technologies. To learn how Sequenom Laboratories is interpreting
the genome for improving the lives of patients everywhere, visit
www.laboratories.sequenom.com and follow @SequenomLabs and
#ACMGMtg.
SEQUENOM®, Sequenom Laboratories™,
HerediT®, MaterniT21® PLUS,
SensiGene® and VisibiliT™, are trademarks of
Sequenom, Inc. All other trademarks and service marks are the
property of their respective owners.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding the development of
innovative products and services and what models of informed
consent may meet the needs of patients, providers, and
laboratories. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Risks
are described more fully in the Company's filings with
the Securities and Exchange Commission, including without
limitation the Company's most recent Annual Report on Form 10-K and
other documents subsequently filed with or furnished to
the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-laboratories-to-present-at-acmg-meeting-300055349.html
SOURCE Sequenom, Inc.